Alpelisib (phosphatidylinositol 3-kinase inhibitor) induced uncontrolled hyperglycemia and colitis
Alpelisib is currently the only Phosphatidylinositol 3-kinase (PI3K) inhibitor approved for treating endocrine therapy-resistant metastatic breast cancer with a Phosphatidylinositol-4,5-bisphosphonate 3-kinase catalytic subunit alpha (PIK3CA)-mutation. Significant side effects of treatment include h...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2024-06-01
|
| Serie: | Current Problems in Cancer: Case Reports |
| Soggetti: | |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S2666621924000176 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|